MedTrace Logo

Impact of Estrogen on Fear Extinction R61

NCT02673606 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2020-07-30

No results posted yet for this study

Summary

The goal of this project is to examine how estrogen may influence the resting-state connectivity and the extinction-induced activation of the fear extinction network.

Conditions

  • Fear
  • Fear; Examination, Phobic

Interventions

DRUG

Estradiol 2Mg Tablet

one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),

DRUG

Estradiol 4Mg Tablet

two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),

DRUG

Placebo Pills

inactive placebo pills

Sponsors & Collaborators

Principal Investigators

  • Mohammed Milad, PhD · NYU School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2019-04-15
Completion
2019-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02673606 on ClinicalTrials.gov